Skip to content
Chlorotrianisene
Tace (chlorotrianisene) is a small molecule pharmaceutical. Chlorotrianisene was first approved as Tace on 1982-01-01. It is used to treat hypogonadism, premature menopause, and prostatic neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
reproductive and urinary physiological phenomenaD012101
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorotrianisene
Tradename
Company
Number
Date
Products
TACESanofiN-008102 DISCN1982-01-01
1 products
TACESanofiN-011444 DISCN1982-01-01
1 products
TACESanofiN-016235 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypogonadismHP_0000815D007006E23.0
premature menopauseHP_0008209D008594E28.31
prostatic neoplasms—D011471C61
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CA: Natural and semisynthetic estrogens, plain
— G03CA06: Chlorotrianisene
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I501——2—3
Cardiovascular diseasesD002318EFO_0000319I98——11—2
Acute liver failureD017114———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10——1——1
Vascular diseasesD014652EFO_0004264I77——1——1
Heart diseasesD006331EFO_0003777I51.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nephrogenic diabetes insipidusD018500N25.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHLOROTRIANISENE
INNchlorotrianisene
Description
Chlorotrianisene is a chloroalkene. It has a role as an estrogen receptor modulator, an antineoplastic agent and a xenoestrogen. It derives from a hydride of a stilbene.
Classification
Small molecule
Drug classNonsteroidal estrogen
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
Identifiers
PDB—
CAS-ID569-57-3
RxCUI2397
ChEMBL IDCHEMBL1200761
ChEBI ID3641
PubChem CID11289
DrugBankDB00269
UNII ID6V5034L121 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 93 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
50,887 adverse events reported
View more details